Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients — Real World Study
Carlos Mario Balcázar-Valencia,Andrés Felipe García-Ramos,Luis Miguel Osorio-Toro,Yessica Alejandra Ordoñez-Guzmán,Nathalia Buitrago-Gómez,William Fernando Cabarcas-López,Carlos Javier Vizcaino-Guerrero,Jorge Enrique Daza-Arana,Alex Ramírez-Rincón,Katherine Restrepo-Erazo
DOI: https://doi.org/10.2147/dmso.s443115
2024-04-10
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Carlos Mario Balcázar-Valencia, 1 Andrés Felipe García-Ramos, 2– 5 Luis Miguel Osorio-Toro, 2, 3, 6 Yessica Alejandra Ordoñez-Guzmán, 3 Nathalia Buitrago-Gómez, 4 William Fernando Cabarcas-López, 7 Carlos Javier Vizcaino-Guerrero, 8 Jorge Enrique Daza-Arana, 2, 9 Alex Ramírez-Rincón, 4 Katherine Restrepo-Erazo 2, 10 1 Specialization in Internal Medicine, Faculty of Health Sciences, Universidad Libre, Santiago de Cali, Colombia; 2 Specialization in Internal Medicine, Faculty of Health, Universidad Santiago de Cali, Santiago de Cali, Colombia; 3 Research and Education Department, Clínica de Occidente S.A., Santiago de Cali, Colombia; 4 Specialization in Endocrinology, Faculty of Health Sciences, Universidad Pontificia Bolivariana, Medellín, Colombia; 5 Specialization in Internal Medicine, Faculty of Health, Universidad del Valle, Santiago de Cali, Colombia; 6 Genetics, Physiology and Metabolism Research Group (GEFIME), Faculty of Health Sciences, Universidad Santiago de Cali, Santiago de Cali, Colombia; 7 Master in Epidemiology, Faculty of Health, Universidad de Caldas, Manizales, Colombia; 8 Specialization in Endocrinology, Faculty of Health, Fundación Universitaria Ciencias de la Salud FUCS, Bogotá, Colombia; 9 Health and Movement Research Group, Faculty of Health Sciences, Universidad Santiago de Cali, Santiago de Cali, Colombia; 10 Specialization in Endocrinology, Faculty of Health, Universidad Nacional de Colombia, Bogotá D.C., Colombia Correspondence: Jorge Enrique Daza-Arana, Specialization in Internal Medicine, Faculty of Health, Universidad Santiago de Cali, Calle 5 &num 62-00, Santiago de Cali, Colombia, Tel/Fax +57 3108923676, Email Purpose: Diabetes is a public health problem that requires strategies to impact glycemic control and reduce the risk of long-term medical complications. Pharmacological management is a necessary treatment for this disease. Therefore, semaglutide is an essential tool to achieve the treatment targets. The present study aimed to evaluate the semaglutide effects on a cohort with type 2 diabetes mellitus (T2DM) in Colombia. Materials and Methods: The cohort included 49 patients with T2DM that have been treated in a specialized care center. Their glycemic outcomes, weight, renal function, and adverse events were evaluated through a 3-, 6- and 12-month follow-up. Results: Significant differences were observed in the outcome evaluation: reduction of glycated hemoglobin levels (MD − 2.74 CI − 1.95 to − 3.52 in 6 months), fasting plasma glucose levels, body weight (MD − 7.11 CI − 5.97 to − 8.24), and the albumin-to-creatinine ratio. The results were maintained throughout the treatment period. The adverse event rate was 16.3%, predominating gastrointestinal events. Conclusion: This real-world evidence shows the efficacy of semaglutide in achieving treatment goals in patients with T2DM. Keywords: semaglutide, diabetes mellitus, glycated hemoglobin A, obesity, glycemic control Type 2 diabetes mellitus (T2DM) is a current public health problem due to its high disease burden. 1 Since the first edition in 2000, the estimated prevalence of diabetes in adults aged 20–79 years has more than tripled, from an estimated 151 million (4.6% of the global population at the time) to 537 million (10.5%) today. Without sufficient action to address the situation, it is estimated that 643 million people will have diabetes by 2023 (11.3% of the population). If trends continue, the number will jump to a staggering 783 million (12.2%) by 2045. 2 These figures are due to the chronicity of the disease and the emergence of new cases. T2DM is characterized by the complexity of its metabolic interactions, where insulin resistance and hyperglycemia play an essential role, 3 resulting in an increased risk of microvascular and macrovascular complications. 4 Because of its implications, DM management requires strategies to reduce risks, positively impact glycemic control, and decrease cardiovascular complications. 5 In addition to structured and individualized nutritional interventions and regular physical activity, most T2DM patients should start a pharmacological treatment. The best-choice medication should be based on individualized targets for glycemic control, comorbidities, life expectancy, and cardiovascular risk. 6 Recently published studies have positioned glucagon-like peptide-1 receptor agonists (GLP1-RAs) in a leading role in metabolic regulation by stimulating glucose-dependent insulin synthesis and secretion, inhi -Abstract Truncated-
endocrinology & metabolism